CoChat

Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome

Blom, Dirk J., Koren, Michael J., Roth, Eli, Monsalvo, Maria Laura, Djedjos, C. Stephen, Nelson, Patric, Elliott, Mary, Wasserman, Scott M., Ballantyne, Christie M., Holman, Rury R. · 2017 · Diabetes, Obesity and Metabolism
Cited by 64

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Aim: To examine the lipid and glycaemic effects of 52 weeks of treatment with evolocumab. Materials and M ethods: The D urable E ffect of PCSK9 A ntibody C ompared with P lacebo S tudy ( DESCARTES ) was a 52‐week placebo‐controlled trial of evolocumab that randomized 905 patients from 88 study centres in 9 countries, with 901 receiving at least one dose of study drug. For this post‐hoc analysis, DESCARTES patients were categorized by baseline glycaemic status: type 2 diabetes, impaired fasting glucose ( IFG ), metabolic syndrome ( MetS ) or none of these. Monthly subcutaneous evolocumab (420 mg) or placebo was administered. The main outcomes measured were percentage change in LDL ‐cholesterol ( LDL‐C ) at week 52 and safety. Results: A total of 413 patients had dysglycaemia (120, type 2 diabetes; 293, IFG ), 289 had MetS (194 also had IFG ) and 393 had none of these conditions. At week 52, evolocumab reduced LDL‐C by >50% in all subgroups, with favourable effects on other lipids. No significant differences in fasting plasma glucose, HbA1c , insulin, C ‐peptide or HOMA indices were seen in any subgroup between evolocumab and placebo at week 52. The overall incidence of new‐onset diabetes mellitus did not differ between placebo (6.6%) and evolocumab (5.6%); in those with baseline normoglycaemia, the incidences were 1.9% and 2.7%, respectively. Incidences of AEs were similar in evolocumab‐ and placebo‐treated patients. Conclusions: Evolocumab showed encouraging safety and efficacy at 52 weeks in patients with or without dysglycaemia or MetS . Changes in glycaemic parameters did not differ between evolocumab‐ and placebo‐treated patients within the glycaemic subgroups examined.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12788

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 64

Metadata

Authors
Blom, D. J., Koren, M. J., Roth, E., Monsalvo, M. L., Djedjos, C. S., Nelson, P., Elliott, M., Wasserman, S. M., Ballantyne, C. M., & Holman, R. R.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2016-10-14
Volume
19
Issue
1
Pages
98-107
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2522643247
Cited by
64
References
19
FWCI
11.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. https://app.cochat.ai/papers/10.1111/dom.12788
The paper
Blom, D. J., Koren, M. J., Roth, E., Monsalvo, M. L., Djedjos, C. S., Nelson, P., Elliott, M., Wasserman, S. M., Ballantyne, C. M., & Holman, R. R. (2017). Evaluation of the efficacy, safety and glycaemic effects of evolocumab ( AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12788

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.